Curaleaf Holdings, Inc. reports developments across its consumer cannabis business, including retail dispensary openings, medical and adult-use product brands, quarterly operating results, and international expansion. The company trades on the Toronto Stock Exchange as CURA and on OTCQX as CURLF.
Recurring updates cover brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, Anthem, and Four 20 Pharma; U.S. dispensary activity; medical cannabis distribution in Germany and other international markets; share repurchase activity; board and shareholder matters; and regulatory topics affecting cannabis operations.
Aurora Cannabis (ACB) responded on September 14, 2026 to Curaleaf Holdings' application to halt Aurora's at-the-market (ATM) share program, in the context of Curaleaf's ongoing hostile bid for Aurora.
Aurora states the ATM program was publicly announced in February 2026, over six months before Curaleaf's bid, and is a long-term capital tool to fund international growth, including recent UK acquisitions. Aurora reports that it is debt free with a strong cash position, while citing Curaleaf financial statements that show more than $1 billion of debt, including $500 million of senior secured notes at 11.5% interest as of June 30, 2026. Aurora's board and special committee have unanimously recommended that shareholders reject Curaleaf's hostile offer by taking no action and not tendering, and advise any shareholders who already tendered to withdraw their shares.
Summary not available.
Curaleaf (CURLF) released a detailed fact sheet supporting its proposal to acquire Aurora Cannabis and contrasting the two companies’ performance and outlook.
Curaleaf states its bid implies a 45% premium to Aurora’s prior trading price, or 110% excluding Aurora’s cash balance*, and describes this as among the higher Canadian M&A premiums of the past decade. The company highlights that Aurora has recorded about C$5 billion of impairments, roughly C$130 million of business transformation costs, and more than C$480 million of negative operating cash flow since FY21, while Curaleaf reports $447 million of positive operating cash flow since FY21. Curaleaf notes cash is about 19% of its US$4.00 offer, the US$5.00 cap equates to a premium within the 92nd percentile of Canadian M&A premiums over 10 years, and says it trades more value on the TSX year‑to‑date than Aurora on Nasdaq.
Curaleaf (CURLF) announced the opening of its Curaleaf Riverview medical cannabis dispensary in Riverview, Florida. With this location, the company now operates 77 dispensaries in Florida and 178 nationwide.
The new store, located at 10422 US Hwy 301 S in the Tampa Bay area, serves a rapidly growing suburban community with convenient access to Tampa, Brandon, Apollo Beach and the South Shore area. The dispensary offers a broad range of medical products, including Curaleaf’s Florida-exclusive Reef flower, Dark Heart ultra-premium flower, FIND flower, Anthem pre-rolls and the Select Briq 2 all-in-one vape.
A grand opening celebration is scheduled for September 18 and 19, 2026, with brand activations, in-store promotions and giveaways while supplies last. Operating hours are Monday through Saturday from 9:00 A.M. to 8:30 P.M. ET and Sunday from 10:00 A.M. to 7:00 P.M. ET.
Curaleaf Holdings (CURLF) announced that members of its executive management team will participate in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference on September 9, 2026.
Executive participants include Executive Vice Chairman Joe Lusardi, Chief Financial Officer Ed Kremer and Chief Investment Officer Camilo Lyon, who will take part in investor meetings in New York City. Investors can find details and webcast access, when available, on Curaleaf’s investor relations website.
Curaleaf (CURLF) responded on September 2, 2026 to Aurora Cannabis (ACB), reaffirming its takeover offer as the best value path for Aurora shareholders, highlighting a 45% premium to Aurora’s unaffected share price and a capped price of US$5.00 per share.
The company states the offer equates to a 110% ex‑cash premium and an implied CY2026E adjusted EBITDA multiple of 12.0x, over 68% above Canadian cannabis peers. It argues the US$5.00 cap still represents an 82% premium to Aurora’s 30‑day VWAP on August 10, 2026 and sits in the 92nd percentile of Canadian M&A premiums over 10 years. Curaleaf contrasts its own cash generation – US$50 million operating cash flow and US$17 million free cash flow in H1 2026, and US$145 million over the last twelve months – and access to US$500 million of senior secured notes, with Aurora’s negative operating cash flow, equity dilution of approximately 31% since 2020, and guidance for lower revenue and adjusted EBITDA by fiscal 2027.
Curaleaf (CURLF) will open a new medical cannabis dispensary in downtown Boston on Friday, September 4, 2026.
Located at 21 Milk St., Boston, MA 02109, near Downtown Crossing, the store offers expanded retail space, broader product selection, and convenient access for patients in Boston and surrounding areas. Patients can purchase products from Curaleaf brands such as Dark Heart, Select, FIND, Anthem and Grassroots, including the Select Briq 2 all-in-one vape device and Select Live Collection. The opening follows the closure of Curaleaf’s former Provincetown dispensary and is presented as part of ongoing investment in Massachusetts.
Aurora Cannabis (ACB) announced that its board unanimously recommends shareholders reject Curaleaf Holdings’ unsolicited hostile takeover bid. The board advises investors to take no action, not tender their shares, and withdraw any shares already tendered.
Aurora states that it is debt free with approximately $149 million in cash, while Curaleaf carries over $1 billion in debt, based on each company’s June 30, 2026 financial statements. The company argues that the offer undervalues Aurora, does not provide an adequate change‑of‑control premium, and would give Curaleaf control over a portion of Aurora’s cash upon closing.
Aurora indicates that, based on the proposed exchange ratio, its shareholders would own about 7.7% of the combined company but hold only about 3.2% of the votes. The board reiterates confidence in Aurora’s standalone plan as a focused global medical cannabis business, highlighting its EU‑GMP manufacturing network, international footprint, and strong balance sheet.
Curaleaf (OTCQX: CURLF) will open a new medical cannabis dispensary in Cutler Bay, Florida, on September 1, 2026, at 11245 SW 211th St., Miami. The store increases Curaleaf's footprint to 76 locations in Florida and 177 nationwide. The dispensary will offer a curated range of brands, including Anthem pre-rolls, Dark Heart flower, Reef flower, and the Select Briq 2 all-in-one vape.
Curaleaf (OTCQX: CURLF, TSX: CURA) issued a detailed response to recent public statements by Aurora Cannabis (TSX: ACB, NASDAQ: ACB) regarding Curaleaf's outstanding offer for Aurora. Curaleaf reiterates that it is offering Aurora shareholders a premium-valued transaction and the chance to participate in what it describes as a larger, stronger global cannabis platform, and says it remains willing to meet at any time to discuss terms.
According to Curaleaf, its proposal is based on Aurora’s latest published figures as of August 5, 2026, and it disputes Aurora’s description of the parties’ prior engagement. Curaleaf highlights, using figures it attributes to Aurora’s own disclosures, multi-year transformation costs exceeding C$400 million, a roughly 35% ACB share-price decline over the year to August 10, 2026 versus a 56% gain in Curaleaf’s shares, a June quarter adjusted EBITDA 63% lower than the March quarter (with C$5.1 million in add-backs), negative C$4.4 million cash flow from operations, and cultivation yields of 114 grams per plant versus more than double that level at Curaleaf. Curaleaf also notes that Aurora’s fiscal 2027 guidance points to lower revenue versus fiscal 2026, margin compression from about 64% to the mid‑to‑high‑50% range, and lower adjusted EBITDA, and states that Aurora’s share price rose materially after the offer announcement and has traded near the implied offer value, which Curaleaf views as support for the strategic rationale.